Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
European Journal of Cancer (Oxford, England : 1990)|February 22, 2017
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative GroupAntonio Irigoyen, Javier Gallego, Carmen Guillén Ponce, et al.
Plos One|August 1, 2020
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registryAlmudena Cotes Sanchís, Javier Gallego, Raquel Hernandez, et al.
Therapeutic Advances in Medical Oncology|July 2, 2021
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registryPaula Jimenez-Fonseca, Alberto Carmona-Bayonas, Alba Martinez-Torron, et al.
Thrombosis and Haemostasis|August 29, 2019
Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with CancerAlberto Carmona-Bayonas, Paula Jimenez-Fonseca, Marcelo Garrido, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 8, 2016
Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancerPaula Jiménez-Fonseca, Alberto Carmona-Bayonas, Maria Luisa Sánchez Lorenzo, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 2, 2021
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM RegistryFelipe Alvarez-Manceñido, Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 24, 2020
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Eva Martínez de Castro, et al.
Pageof 6